Literature DB >> 5530275

Plaque assay for pneumonia virus of mice.

G Shimonaski, P E Came.   

Abstract

A plaque assay for the quantitation of pneumonia virus of mice is described. To obtain reproducible plaque formation, proteolytic enzymes had to be incorporated in the overlay medium. The plaque morphology observed in the presence of pancreatin and chymotrypsin was superior to that seen with trypsin. Although the plaque assay was found to be slightly less sensitive than the TCID(50) determination described by Harter and Choppin, it enables cloning of the virus by plaque selection and permits further study of pneumonia virus of mice.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5530275      PMCID: PMC377044          DOI: 10.1128/am.20.5.775-777.1970

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  4 in total

1.  INTERACTION OF MYXOVIRUSES WITH DEXTRAN SULFATES. II. SPECTRUM OF INHIBITORY ACTIVITY. CHARACTERISTICS OF ANTIVIRAL EFFECTS OF DEXTRAN SULFATES IN TISSUE CULTURE.

Authors:  B STYK; B RADA
Journal:  Acta Virol       Date:  1964-07       Impact factor: 1.162

2.  INFLUENCE OF ACID POLYSACCHARIDES ON PLAQUE FORMATION BY INFLUENZA A2 AND B VIRUSES.

Authors:  K K TAKEMOTO; P FABISCH
Journal:  Proc Soc Exp Biol Med       Date:  1963-12

3.  Effect of pancreatin on plaque formation by influenza viruses.

Authors:  P E Came; A Pascale; G Shimonaski
Journal:  Arch Gesamte Virusforsch       Date:  1968

4.  Studies on pneumonia virus of mice (PVM) in cell culture. I. Replication in baby hamster kidney cells and properties of the virus.

Authors:  D H Harter; P W Choppin
Journal:  J Exp Med       Date:  1967-08-01       Impact factor: 14.307

  4 in total
  1 in total

1.  Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy.

Authors:  Kevin B Walsh; John R Teijaro; Linda G Brock; Daniel M Fremgen; Peter L Collins; Hugh Rosen; Michael B A Oldstone
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.